Affiliation:
1. Department of Cardiology Sun Yat‐Sen Memorial Hospital, Sun Yat‐Sen University Guangzhou China
2. Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology Guangzhou China
3. Guangzhou Key Laboratory of Molecular Mechanism and Translation in Major Cardiovascular Disease, Sun Yat‐Sen Memorial Hospital Sun Yat‐Sen University Guangzhou China
4. Department of Endocrine The Second Affiliated Hospital of Nanchang University Jiangxi
5. Department of Pharmacology and Systems Physiology University of Cincinnati College of Medicine Cincinnati OH
6. Department of Cardiology The First Affiliated Hospital of Sun Yat‐Sen University Guangzhou China
Abstract
Background
B‐type natriuretic peptide (BNP) is a well‐known biomarker for prognosis in heart failure with patients with preserved ejection fraction. However, the clinical predictive ability of BNP for the risk of stroke in HFpEF is not clear.
Methods and Results
A total of 799 patients with HFpEF from the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial were included. Association of baseline BNP with risk of stroke was assessed using the Cox proportional hazard model. The discriminatory ability of BNP was expressed using the C index. The improvement in 5‐year stroke prediction was assessed by C statistic, categorical net reclassification improvement index, and relative integrated discrimination improvement. A total of 34 (4.3%) patients among the 799 patients with HFpEF experienced stroke events over a median of 2.85 years of follow‐up. The stroke group showed a higher BNP level than the nonstroke group (375 pg/mL versus 241 pg/mL, respectively;
P
=0.006). Higher BNP levels were associated with increased risk of stroke after multivariable adjustment (hazard ratio, 3.29 [95% CI, 1.51–7.16]) and had a moderate performance for stroke prediction (C index, 0.67). Adding BNP to CHADS
2
/CHA
2
DS
2
‐VASc/R
2
CHADS
2
scores improved their predictive value for stroke (CHADS
2
: C index, 0.67; BNP+CHADS
2
: C index, 0.77; net reclassification improvement, 40.9%; integrated discrimination improvement, 3.0%; CHA
2
DS
2
‐VASc: C index, 0.64; BNP+CHA
2
DS
2
‐VASc: C index, 0.74; net reclassification improvement, 41.4%; integrated discrimination improvement, 2.2%; R
2
CHADS
2
: C index, 0.70; BNP+R
2
CHADS
2
: C index, 0.78; net reclassification improvement, 40.9%; integrated discrimination improvement, 3.2%).
Conclusions
BNP is associated with an increased risk of stroke in patients with HFpEF and may be a valuable biomarker for stroke prediction in HFpEF.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献